366 results on '"Davey, Richard T"'
Search Results
2. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
3. Lassa Virus Infection: a Summary for Clinicians
4. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial
5. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial
6. South American Hemorrhagic Fevers: A summary for clinicians
7. Maintaining Momentum in Clinical Trials for Respiratory Viruses*
8. Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design
9. The Past Need Not Be Prologue : Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection
10. Ebola virus disease: an update on post-exposure prophylaxis
11. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study
12. CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Meta-Analysis of 3 Vanguard Studies
13. Evidence of Ebola Virus Replication and High Concentration in Semen of a Patient During Recovery
14. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial
15. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study
16. Short-Cycle Structured Intermittent Treatment of Chronic HIV Infection with Highly Active Antiretroviral Therapy: Effects on Virologic, Immunologic, and Toxicity Parameters
17. High-Level HIV-1 Viremia Suppresses Viral Antigen-Specific CD4 + T Cell Proliferation
18. HIV-1 and T Cell Dynamics after Interruption of Highly Active Antiretroviral Therapy (HAART) in Patients with a History of Sustained Viral Suppression
19. New filovirus disease classification and nomenclature
20. Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus
21. Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study
22. Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015
23. Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study
24. A Single Case Observation: Is the Ebola Virus Soluble Glycoprotein an Indicator of Viral Recrudescence?
25. Ethical and Practical Considerations in Providing Critical Care to Patients With Ebola Virus Disease
26. State-of-the-Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola Virus
27. Validation of the Wild-type Influenza A Human Challenge Model H1N1pdMIST: An A(H1N1) pdm09 Dose-Finding Investigational New Drug Study
28. Supplement to: A recombinant vesicular stomatitis virus Ebola vaccine.
29. Safety, tolerability, and pharmacokinetics of radavirsen (AVI‐7100), an antisense oligonucleotide targeting influenza a M1/M2 translation
30. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies
31. Asymptomatic Solitary Pulmonary Nodules Due to Cryptococcus neoformans in Patients Infected with Human Immunodeficiency Virus
32. Supplement to: Clinical management of Ebola virus disease in the United States and Europe.
33. Trial of ZMapp for Ebola Virus Infection
34. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
35. Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations--United States, 2021
36. CD4 T Cell Survival after Intermittent Interleukin-2 Therapy Is Predictive of an Increase in the CD4 T Cell Count of HIV-Infected Patients
37. CD4⁺ T Cell Responses to Interleukin-2 Administration in HIV-Infected Patients Are Directly Related to the Baseline Level of Immune Activation
38. Clinical Management of Ebola Virus Disease in the United States and Europe
39. A Proof-of-Concept Study of Short-Cycle Intermittent Antiretroviral Therapy with a Once-Daily Regimen of Didanosine, Lamivudine, and Efavirenz for the Treatment of Chronic HIV Infection
40. A Randomized, Double-Blinded, Placebo-Controlled Trial of Intermittent Administration of Interleukin-2 and Prednisone in Subjects Infected with Human Immunodeficiency Virus
41. Long-Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and on Immunologic and Virologic Parameters
42. Pilot Study of the Effects of Intermittent Interleukin-2 on Human Immunodeficiency Virus (HIV)-Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection
43. Human Immunodeficiency Virus Type 1 Quasi Species That Rebound after Discontinuation of Highly Active Antiretroviral Therapy Are Similar to the Viral Quasi Species Present before Initiation of Therapy
44. Effects of Intermittent Interleukin-2 Therapy on Plasma and Tissue Human Immunodeficiency Virus Levels and Quasi-Species Expression
45. A Randomized, Controlled, Phase II Trial Comparing Escalating Doses of Subcutaneous Interleukin-2 plus Antiretrovirals versus Antiretrovirals Alone in Human Immunodeficiency Virus-Infected Patients with CD4⁺ Cell Counts ⩾350/mm³
46. Interleukin-2 up-Regulates Expression of the Human Immunodeficiency Virus Fusion Coreceptor CCR5 by CD4⁺ Lymphocytes in vivo
47. Hepatitis G Virus and Human Immunodeficiency Virus Coinfection: Response to Interferon-α Therapy
48. Caring for Critically Ill Patients Infected With the Ebola Virus
49. Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States
50. Challenges in Managing Patients who have Suspected or Confirmed Ebola Virus Infection at the National Institutes of Health
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.